Skip to content
Atlas Research Compounds

Semax vs. Cortagen

A structured research comparison between Semax and Cortagen across compound identity, research category, evidence maturity, and interpretation boundaries.

ACTH-fragment-derived neuropeptide

Semax

Investigated across neurotrophic, transcriptional, and stress-response signaling; no single mechanism explains the full literature.

Evidence score2/5

Early human evidence

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Open full profile →

Short peptide bioregulator

Cortagen

Proposed as a tissue-associated short peptide bioregulator; target-level evidence remains limited.

Evidence score1/5

Preclinical foundation

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Open full profile →

Side-by-side research context

DimensionSemaxCortagen
Catalog identitySemax is mapped to ACTH-fragment-derived neuropeptide research.Cortagen is mapped to short peptide bioregulator research.
Research categorySemax is primarily organized around neuroprotection and cognition research.Cortagen is primarily organized around neural bioregulator models.
Interpretive boundaryUse the Semax profile and verified study pages before inferring mechanism or outcomes.Use the Cortagen profile and verified study pages before inferring mechanism or outcomes.

Combined literature starting points

Comparison pages organize differences; they do not establish superiority, equivalence, or individual suitability.

  1. 01

    Semax literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source
  2. 02

    Atlas internal research database

    Internal Research Database · 2026 · Database

    Open source
  3. 03

    Short peptide bioregulator literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source